Clinical Trial Update: A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057 [Phase 3]

View source ↗

Summary

Continuation Phase 3 trial for lupus patients who completed prior HGS1006 studies completed; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• HGS1006

Snippet

Sponsor: Human Genome Sciences Inc., a GSK Company | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: COMPLETED | Results posted: 2018-01-16